CN Patent

CN116583277A — 药物中的降解化合物

Assigned to Vision Therapy Co ltd · Expires 2023-08-11 · 3y expired

What this patent protects

本公开涉及包含碳酰胆碱、溴莫尼定(brimonidine)和少于5％的一种或多种杂质的眼用制剂；用于制备包含碳酰胆碱、溴莫尼定和少于5％的一种或多种杂质的眼用制剂的方法；以及通过施用包含碳酰胆碱、溴莫尼定和少于5％的一种或多种杂质的眼用制剂来治疗老花眼和其它眼科病症的方法。

USPTO Abstract

本公开涉及包含碳酰胆碱、溴莫尼定(brimonidine)和少于5％的一种或多种杂质的眼用制剂；用于制备包含碳酰胆碱、溴莫尼定和少于5％的一种或多种杂质的眼用制剂的方法；以及通过施用包含碳酰胆碱、溴莫尼定和少于5％的一种或多种杂质的眼用制剂来治疗老花眼和其它眼科病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116583277A
Jurisdiction
CN
Classification
—
Expires
2023-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Vision Therapy Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.